IKZF1 and plasma cell myeloma: CFT7455 targets Ikaros and Aiolos, two zinc-finger transcription factors that are regulators of lymphoid development and differentiation and is in phase I trials for the treatment of refractory NHL or multiple myeloma (NCT04756726) [77].